Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Mallisalkku: Revenion paino nousee salkussa osakeannin myötä

REG1VResearch28.09.2026 klo 10.11
Juha Kinnunen, Atte Riikola, Rauli Juva
Discuss
Download report (PDF)This report is only available for Inderes Premium customers.

Mallisalkku käyttää kaikki Revenion merkintäoikeutensa ja osti lisäksi 471 oikeutta, joilla merkitsemme yhtiön merkintäoikeusannissa yhteensä 756 uutta osaketta 6,19 euron kappalehintaan. Kokonaissijoituksemme on noin 5 600 euroa. Teimme toimenpiteet maanantaina 28.9. kun merkintäaika ja kaupankäynti merkintäoikeuksilla alkoi. Annin jälkeen Revenion paino Mallisalkussa on noin 8 % ja käteispaino noin 7 %.

Login required

This content is only available for logged in users

Create account

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Read more on company page

Key Estimate Figures23.09.

202526e27e
Revenue109.7200.2269.6
growth-%6.0 %82.5 %34.7 %
EBIT (adj.)26.532.244.8
EBIT-% (adj.)24.2 %16.1 %16.6 %
EPS (adj.)0.580.670.67
Dividend0.000.000.00
Dividend %
P/E (adj.)33.016.015.8
EV/EBITDA16.719.211.1

Forum discussions

Nyt meni merkitseminen läpi kun rahat tuli T+2 pv ajassa OSTin hoitotilille. Se ei siis riitä, että OSTilta myy osakkeita ja saa varat käytett...
9/30/2026, 7:35 AM
by palse
7
Jahas, taisi Caravelle saada eilen hankittua haluamansa määrän merkkareita ja nyt niiden kurssi sukeltaa.
9/30/2026, 7:11 AM
by Kryptoniitti
3
I just realized that Revenio’s rights issue presentation webcast was today. A couple of approvals and registration are required before you can...
9/29/2026, 5:44 PM
by NukkeNukuttaja
4
“We used to have a very highly profitable company → well, now it’s a lot less profitable company Return on capital was high → well, now it’s...
9/29/2026, 3:10 PM
by Optis
26
Yesterday’s arbitrage of about €0.20/share melted away today. According to Nordnet’s broker statistics, all the big net buyers today were American...
9/29/2026, 2:09 PM
by Juurikki
5
I think so too, and yes, subscription rights can only be bought for a traditional osakeopstitiili (AOT) [share savings account]. Let’s see if...
9/29/2026, 10:45 AM
by palse
1
Of course, you can subscribe to new issues with an equity savings account (OST), but you can’t buy subscription rights (merkkari) because you...
9/29/2026, 10:22 AM
by FanTom
5